Wedbush Maintains Neutral on Sionna Therapeutics, Raises Price Target to $6
Wedbush analyst Laura Chico maintains Sionna Therapeutics (NASDAQ:SION) with a Neutral and raises the price target from $5 to $6.
Stocks · News reference
Sionna Therapeutics To Advance SION-451/SION-2222 CF Combo Into Phase 2a; Cuts Workforce By 46% To Extend Cash Runway Into The Second Half Of 2029
Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activityDual combination Phase 2a trial expected to initiate
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Sionna Therapeutics, Inc. (SION)
Filed: 2026-09-14 AccNo: 0001193125-26-390577 Size: 200 KB Item 2.05: Cost Associated with Exit or Disposal Activities Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Sionna Therapeutics Inc on Behalf of Sionna Therapeutics Stockholders and Encourages Investors to Contact the Firm
Law firm Bragar Eagel & Squire is investigating Sionna Therapeutics after the company announced its SION-719 Phase 2a trial failed to achieve its primary endpoint for sweat chloride reduction. The stock price fell over 91% following the announcement. The firm is encouraging affected shareholders to contact them regarding potential securities law violations.